Clinical Trial Update: Betaglucin 0.2% Versus Imiquimod 5% in Treatment of Ano-genital Warts: Combined Results From Triple Blind Controlled Study [Phase 3]

View source ↗

Summary

Phase 3 trial comparing Betaglucin 0.2% to Imiquimod 5% for genital warts shows results from a triple-blind controlled study.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Genital Wart Virus Infection
• Genital Warts

Drugs mentioned

• Betaglucin 0.2% (Betaglucin 0.2%)
• Imiquimod 5% (Imiquimod 5%)

Snippet

Sponsor: Centro de Investigaciones Medicas y Ensayos Clinicos Dr Italo Fabbri | Conditions: Genital Wart Virus Infection | Phase 3 | Status: UNKNOWN